A biostatistician in New Jersey who consulted for pharmaceutical companies used insider information to buy stock before positive drug trial results were announced, netting nearly $500,000 in profits, federal prosecutors said.
Hong Wang and his company Precision Clinical Consulting LLC violated federal securities laws by trading on material nonpublic information, according to a complaint the Securities and Exchange Commission filed Wednesday in the US District Court for the District of Massachusetts.
Wang worked as a consultant for Watertown, Mass.-based C4 Therapeutics Inc. from June 2023 to June 2024, analyzing clinical trial data for a cancer drug. He allegedly learned about ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.